Investment Summary

Exits Affymax

On December 15, 2006, invested in life science company Affymax from Apax and Nexus Life Science Partners

Investment Highlights
  • This is transaction in the Life Science sector.
  • This is transaction in the United States.
  • This is transaction in California.

Investment Summary

Date 2006-12-15
Target Affymax
Sector Life Science
Sellers(s) Apax
Nexus Life Science Partners
Deal Type IPO

Target

Affymax

Cupertino, California, United States
website
Affymax is a biopharmaceutical company focused on anemia in kidney disease and cancer. Affymax was established in 2001 and is based in Cupertino, California.

Search 177,612 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Seller(S) 2

SELLER

Apax

London, United Kingdom

Investor Investor Investor Investor Investor

website


Category Private Equity Firm
Founded 1981
PE ASSETS 60.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Apax Partners is a mega-sized private equity investment group, operating across the United States, Europe, Israel and Asia. Broad industry sectors of interest include tech & telecom, media, retail & consumer, healthcare, financial services, and business services. Apax will consider both minority and majority investment positions and prefers companies with strong market positions and growth potential. The Firm generally pursues platform acquisitions valued from €1 to €5 billion. Apax Partners was formed in 1981 and is based in London.


DEAL STATS #
Overall 16 of 162
Sector (Life Science) 2 of 6
Type (IPO) 5 of 25
State (California) 1 of 13
Country (United States) 5 of 63
Year (2006) 5 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2006-12-04 Plantasjen

Kongsvinger, Norway

Plantasjen is a garden superstore chain in the Nordic region, providing a wide assortment covering the customers entire need for garden and terrace products as well as decorative flowers and in-house plants. Plantasjen was established in 1986 and is based in Kongsvinger, Norway.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2006-12-18 Incisive Media

London, United Kingdom

Incisive Media is a business-to-business (B2B) information provider, serving a wide range of financial, business technology, and professional services markets globally. The company provide analyst-grade insight, business intelligence, and access to specialist networks of business professionals around the globe. Its performance-driven marketing solutions give clients bespoke engagement with these valuable audiences and communities. Incisive Media was formed in 1994 and is based in London.

Buy £199M
SELLER

Nexus Life Science Partners

New York, New York, United States

website


Category Growth Capital Firm
Founded 2001
Size Small
Type Sector Focused
DESCRIPTION

Nexus Life Science Partners is a private equity firm that targets private and public healthcare companies located within the United States and around the world. The Firm's focus is on the growth segments of the healthcare industry. In particular, Nexus looks for product-driven life sciences companies developing breakthrough therapeutics for clinical needs, positively altering disease course and associated costs. The firm seeks for each private investment a potential for liquidity within 24 months after initial investment, as well as a 2-3 times return on invested capital. Nexus Life Science Partners was formed in 2001, and is based in New York, New York.


DEAL STATS #
Overall 7 of 22
Sector (Life Science) 6 of 18
Type (IPO) 3 of 6
State (California) 2 of 6
Country (United States) 6 of 19
Year (2006) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2006-05-15 Cambridge Antibody Technology

Gaithersburg, United Kingdom

Cambridge Antibody Technology (CATG) is a leader in the development of human monoclonal antibodies as new treatments for disease, having developed a pipeline of novel human monoclonal antibodies. HUMIRA, an antibody for the treatment of rheumatoid arthritis, developed in collaboration with Abbott, is on the market.

Sell $702M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2007-02-08 Cougar Biotechnology

Raritan, New Jersey, United States

Cougar Biotechnology (CGRB) is a biotechnology company established to in-license and develop oncology drugs. Cougar's oncology portfolio includes CB7630, a targeted enzyme inhibitor, which is currently being tested in Phase II clinical trials in prostate cancer; other products are being tested for hematological and solid tumors.

Sell -